Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01991795 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 19,271
- Enrollment target
NCT01991795: Completed Phase 3 study, sponsored by AstraZeneca.
NCT01991795 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 19,271 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2399% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01991795, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 19,271 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
Primary Outcome
Participants with Cardiovascular (CV) death, myocardial infarction (MI) or stroke. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and non-CV death date.
Interventions
- DRUG Ticagrelor 60 mg
- DRUG Ticagrelor placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19,271 participants |
| Start Date | 2014-02-10 |
| Est. Completion | 2019-01-25 |
| Phase | Phase 3 |
What the finished NCT01991795 record still lists
NCT01991795 is an interventional study that assigns participants to a tested intervention. Its 19,271 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2399% higher).
The record links to 0 conditions, and to 2 interventions - of which Ticagrelor 60 mg is the first listed.
NCT01991795 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01991795 about?
NCT01991795 is a clinical study titled "A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus". The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
What is the current status of trial NCT01991795?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 19,271 participants. The study started on 2014-02-10. Estimated completion is 2019-01-25.
What interventions are being tested in trial NCT01991795?
The interventions under investigation include: Ticagrelor 60 mg (DRUG), Ticagrelor placebo (DRUG).
Who is sponsoring clinical trial NCT01991795?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01991795's enrollment target sits among peer trials
19,271 11th of 2000 higher than 1,990 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05555095 · 19,331 participants
Examining Digital Health Care Delivery Models Through Medicaid Collaborative
- NCT07152249 · 19,480 participants · NA
Advancing Strategies to Optimize the PerIopeRativE Management of PostOperative Nausea and Vomiting (ASPIRE-PONV) Trial
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI